F. Boyle

Management of Alopecia Due to Cancer Therapies

H. Rugo, M. Lacouture, G. Fogarty, 2018 .

Chemotherapy induced alopecia and strategies to manage its impact

F. Boyle, J. Shaw, 2017 .

Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy

P. Grimison, M. Kiernan, Susanna B. Park, 2022, Supportive Care in Cancer.

Measurement of chemotherapy-induced alopecia—time to change

A. Young, C. V. D. Hurk, F. Boyle, 2015, Supportive Care in Cancer.

Electrophysiological and phenotypic profiles of taxane-induced neuropathy

D. Goldstein, M. Kiernan, Susanna B. Park, 2020, Clinical Neurophysiology.

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

Suzanne F. Jones, M. Koehler, J. Crown, 2008, Breast Cancer Research and Treatment.

Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer

L. Horvath, D. Goldstein, P. Grimison, 2017, Clinical Neurophysiology.

Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.

H. Rugo, J. O’Shaughnessy, M. Gumus, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Human botfly infestation presenting as a labial abscess: Travel history matters

N. Price, F. Boyle, I. Currie, 2008, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review

T. Libermann, B. Oh, N. Pavlakis, 2021, Frontiers in Oncology.

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

K. Gelmon, G. Curigliano, D. Cameron, 2020 .